Tag
This study reveals that lower brain iron levels in the substantia nigra-ventral tegmental area are associated with elevated striatal dopamine synthesis in schizophrenia, highlighting a potential new target for therapeutic intervention.
This study reveals reduced brain iron in the substantia nigra-ventral tegmental area correlating with increased striatal dopamine synthesis in schizophrenia, suggesting novel neurobiological mechanisms and potential therapeutic targets.
An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.
A multicenter randomized trial comparing seven antipsychotics in acute schizophrenia shows olanzapine and risperidone outperform several agents in efficacy but differ markedly in side effects, clarifying treatment choices.
This study reveals region- and size-specific dendritic spine deficits in cortical layer 3 neurons of schizophrenia patients, highlighting differential synaptic disruptions across visual and prefrontal cortical areas underpinning cognitive d
The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi
This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.
This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonst
This study reveals an increased risk of infections among schizophrenia patients treated with clozapine compared to olanzapine, highlighting the need for vigilant infection monitoring and preventive care.
Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Two randomized controlled trials evaluated immersive VR therapies targeting auditory verbal hallucinations and persecutory delusions in schizophrenia and psychosis, revealing modest benefits for hallucinations but no superior effect for cog
